Sarcomatoid Carcinoma Of Bladder Research Articles

A Scarce Case of Sarcomatoid Bladder Carcinoma and Bladder Stone in a 58-Year-Old Man: A Case Report

BACKGROUND: Sarcomatoid bladder carcinoma is scarcely found, with most cases of bladder carcinoma due to bladder stone as a risk factor consisting of squamous cell carcinoma. Only 221 cases were reported between 1973 and 2004 of sarcomatoid bladder cancer. Therefore, this case report brings out sarcomatoid bladder carcinoma and its clinical relevance. CASE DESCRIPTION: A 58 years old Indonesian man experienced gross hematuria for 3 months, and thus finally brought to the Emergency Room (ER) where he was initiated urinary catheter and given intravenous (IV) fluid along with analgesic parenterally. Emergency abdominal radiograph assessment and blood test were made. Abdominal radiograph assessment suggests a 6 x 6 cm opacity in the bladder and several urolithiasis in the pelvic cavity. Ureum and creatinine increased in the blood test procedure. Based on the characteristic appearance and radiological findings, a diagnosis of vesicolithiasis was made. Following the diagnosis, the patient was urgently operated on (Open vesicolithotomy), and during the stone removal, there was a tangled polyp-like mass found buried underneath the stone. Histological findings of mass and surrounding lymph nodes were made and histopathologically stated the mass was sarcomatoid carcinoma of the bladder and it had metastated to lymph node and pelvic region. CONCLUSION: Considering hematuria in urolithiasis is frequent, the clinician should be aware of any tumor findings especially when the hematuria is massive thus emergency urolithotomy should be considered immediately.

Bladder Sarcomatoid Carcinoma in an Adolescent: 10-Year Survival After Aggressive Surgical Management

Bladder Sarcomatoid Carcinoma in an Adolescent: 10-Year Survival After Aggressive Surgical Management

One case report of Bladder sarcomatoid carcinoma

目的 探讨临床膀胱肉瘤样癌的治疗方法。 方法 报告1例临床膀胱肉瘤样癌病例，采取膀胱部分切除术治疗。 结果 本例患者行膀胱部分切除术和化疗，行膀胱灌注化疗及膀胱镜检查两次，局部未见有肿瘤复发，患者手术后9个月生存期无明显生活质量影响，对于膀胱肉瘤样癌患者全膀胱切除并不能延长生存期，外科医师在手术时应参考其他情况综合考虑，从而选择个性化的手术方式。 结论 膀胱肉瘤样癌早期诊断和采用手术切除仍是首选治疗方式，临床分期与生存期的关系有待进一步研究。

The natural history, treatment pattern, and survival of the patients with sarcomatoid bladder carcinoma: A pooled analysis.

e15532 Background: Sarcomatoid bladder carcinoma (SRBC) is a rare variant of urothelial cancer. Current data is limited on clinical features, appropriate management and outcomes. Methods: A retrosp...

Sarcomatoid bladder carcinoma: A rare metastatic disease of small bowel

Introduction: Small bowel obstruction secondary to metastatic disease is a rare presentation with most current evidence being limited to case reports. Previous evidence described breast, lung and melanoma as the most common underlying primaries presenting with this entity. Bladder carcinoma rarely metastasizes to the gastrointestinal tract, and if present, does not typically cause small bowel obstruction. Case Report: A 62­year­old female with a history of sarcomatoid bladder carcinoma that had been managed initially by transurethral endoscopic resections and subsequently by a radical cystectomy presented a year later with small bowel obstruction. Extensive work­up for the source of the obstruction was inconclusive and after failed conservative management, the patient underwent an exploratory laparotomy. At laparotomy, she was found to have a small bowel intussusception secondary to a tumor. The small bowel resection specimen was later identified as a sarcomatoid carcinoma, resembling the previously resected bladder tumor. Conclusion: We present a rare case of a patient presenting with small bowel obstruction secondary to metastatic disease from a variant of bladder cancer—the sarcomatoid bladder carcinoma.

IS4-1 - A Phase I Dose-Escalation Study of emd 1214063, an Oral Selective CMET Inhibitor, in Patients with Advanced Solid Tumors

ABSTRACT Background The cell surface receptor tyrosine kinase c-Met and its ligand, the hepatocyte growth factor (HGF), are implicated in tumor cell migration, invasion, survival and proliferation. EMD 1214063 is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor. Methods This is a phase I, first in human (FIH) clinical trial with escalating doses of EMD 121406(NCT 01014936). The primary objective is to determine the MTD. Secondary objectives include evaluation of safety, pharmacokinetics, anti-tumor effect and pharmacodynamics (Pd). Eligible patients had advanced solid tumors not amenable to standard therapies. Following a classical 3 + 3 dose escalation scheme, successive cohorts of patients were treated with once daily oral EMD 1214063 according to two 21-day-cycle schedules, either days 1-14 followed by a 7-day rest(regimen 1, R1), or continuous three times weekly administration (regimen 2, R2). Pd markers were evaluated in paired tumor biopsies. Results As of 30 March 2011, a total of 41 patients had been enrolled, 21 in R1 and 20 in R2. The dose was escalated from 30 mg/day to 115 mg/day in R2 and to 230 mg/day in R1. One DLT was reported in R1 at 115 mg/day, an asymptomatic, grade 4 lipase and G3 amylase elevation. No other DLTs or treatment-related SAEs were observed. The remaining treatment-related AEs of grade 2 or higher included nausea (n = 1), vomiting (n = 1), anorexia (n = 1), diarrhea (n = 1), and fatigue (n = 1) in R1, and neutropenia (n = 1) in R2. 37 patients (90%) had no drug-related toxicity greater than grade 1. At the dose levels investigated, median Cmax and AUC values increased with dose. Immunohistochemical analysis of a patient with pre- and on-treatment biopsies showed a decrease in phospho-c-Met staining intensity under treatment. Preliminary anti-tumor activity has been observed, including an unconfirmed PR in one patient and stable disease lasting for at least 4 months in 5 patients. One patient with sarcomatoid bladder carcinoma and multiple MET copies due to polysomy of chromosome 7 achieved SD for 16+ months. Conclusions The MTD has not yet been reached and dose escalation of EMD 1214063 continues. Updated results of this FIH study will be presented.

Sarcomatoid Carcinoma in the Urinary Bladder

Sarcomatoid carcinoma of the urinary bladder is a rare malignant neoplasm in which the tumor consists of both carcinomatous and sarcomatous elements. In Korea, only 1 case of bladder and renal pelvis primary sarcomatoid carcinoma and 4 cases of carcinosarcoma involving the bladder have been reported. Recently, we experienced a case of sarcomatoid carcinoma of the bladder in a 78-year-old male patient experiencing severe gross hematuria. An ultrasound demonstrated a broad-based tumor 4.5×3.6 cm in size on the lateral side of the right ureteral orifice in the bladder dome. Under the diagnosis of a bladder tumor, transurethral resection of the bladder tumor (TURBT) was performed. A subsequent histological examination of the biopsy specimens showed both malignant mesenchymal and epithelial elements. As a result, the tumor was pathologically confirmed as a primary sarcomatoid carcinoma of the urinary bladder.

Clinical Features of Sarcomatoid Carcinoma (Carcinosarcoma) of the Urinary Bladder: Analysis of 221 Cases

Background. Urinary bladder sarcomatoid carcinoma (carcinosarcoma) is rare. The objective of this study was to examine the epidemiology, natural history, and prognostic factors of urinary bladder carcinosarcoma using population-based registry. Methods. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify cases by tumor site and histology codes. The association between clinical and demographic characteristics and long-term survival was examined. Results. A total of 221 histology confirmed cases were identified between 1973 and 2004, this accounted for approximately 0.11% of all primary bladder tumors during the study period. Median age of the patients was 75 years (range 41–96). Of the patients with a known tumor stage (N = 204), 72.5% had a regional or distant stage; 98.4% of patients with known histology grade (N = 127), had poorly or undifferentiated histology. Multiple primary tumors were indentified in about 40% of study subjects. The majority of patients (95.9%) received cancer directed surgery, 35.8% had radical or partial cystectomy, 15.8% of patients received radiation therapy combination with surgery. The median overall survival was 14 months (95% CI 7–21 months). 1-, 5-, and 10-year cancer specific survival rate were 53.9%, 28.4% and 25.8%. In a multivariate analysis, only tumor stage was found to be a significant prognostic factor for disease-specific survival. Conclusions. Urinary bladder carcinosarcoma commonly presented as high grade, advanced stage and aggressive behavior with a poor prognosis. Emphasis on early detection, including identification of risk factors is needed to improve the outcome for patients with this malignancy.

Empleo de M-VAC en el tratamiento adyuvante del carcinoma sarcomatoide de vejiga

Sarcomatoid bladder carcinoma is a high-grade neoplasm and accounts for approximately 0,3% of all bladder malignancies. sarcomatoid carcinoma originates from transitional cells of the bladder. sarcomatoid carcinoma is charactericed by a epithelial component and a sarcomatoid component, consisting of spindle cells, that is only epithelial marker-positive. we report a 26 year-old woman diagnosed of stage iii sarcomatoid bladder carcinoma (t3an0m0) treated with partial cistectomy followed by 4 cycles of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.

Isolated bladder metastasis causing large bowel obstruction: a case report of an atypical presentation of intussusception

Intussusception of the large bowel is a rare clinical entity. In adults, this pathology is usually associated with a malignant lead point and often requires operative management. Reported is the case of an 83-year-old female who was recently diagnosed with superficial bladder cancer (T1) treated by partial cystectomy. She presented 3 months post-operatively with an isolated mucosal metastasis of the transverse colon causing intussusception and large bowel obstruction. The patient was successfully treated by colonic resection with primary anastomosis. Histology was significant for a pedunculated sarcomatoid bladder carcinoma originating from the colonic mucosa with incomplete invasion of the bowel wall. An isolated mucosal metastasis of this variety has not been reported in the literature to date.

Sarcomatoid carcinoma with osseous differentiation in the bladder

Bladder sarcomatoid carcinoma is a very rare variant of transitional cell carcinoma. With disputed nomenclature, the tumor has been described previously under a variety of names such as sarcomatoid carcinoma, pseudosarcoma, malignant mixed mesodermal/Müllerian tumor, metaplastic carcinoma and spindle cell carcinoma. This malignancy represents 0.3% of all bladder tumors and has an aggressive behavior yielding a poor prognosis despite radio and chemotherapy. An 81 y/o man presented with a transitional cell carcinoma and underwent a transurethral resection. Adjuvant onco-BCG was introduced. After 9 months of follow-up, a local tumoral recurrence occurred and a new transurethral resection revealed sarcomatoid carcinoma with osseous elements. A radical cystoprostatectomy was then carried out.

Sarcomatoid bladder carcinoma

A case of sarcomatoid bladder carcinoma, which had infiltrated the posterior wall and the trigone in an 81-year-old patient is described. The histological results showed a double component (mesenchymal and epithelial) with transition areas between the two and a positivity for HCG, but no typical morphological pattern of choriocarcinoma. The patient underwent radical cystectomy with urinary diversion.

SARCOMATOID CARCINOMA OF THE URINARY BLADDER

Sarcomatoid carcinoma of the urinary bladder is a rare malignancy of an aggressive nature usually seen in patients in the seventh to eighth decade of life. A case of sarcomatoid carcinoma of the bladder in a 37 year old male presenting with gross haematuria is reported. A potency-preserving radical cystoprostatectomy with ileal conduit was performed.